An Emerging Role of KRAS in Biogenesis, Cargo Sorting and Uptake of Cancer-Derived Extracellular Vesicles

References

• Munoz-Maldonado C , ZimmerY , MedovaM. A comparative analysis of individual RAS mutations in cancer biology. Front. Oncol.9, 1088 (2019).
   PubMed Web of Science ®Google Scholar
• Cefalì M , EpistolioS , PalmarocchiMC , FrattiniM , DeDosso S. Research progress on KRAS mutations in colorectal cancer. J. Cancer Metastasis Treat.7, 26 (2021).
   Google Scholar
• Pantsar T . The current understanding of KRAS protein structure and dynamics. Comput. Struct. Biotechnol. J.18, 189–198 (2020).
   PubMed Web of Science ®Google Scholar
• Waters AM , DerCJ. KRAS: the critical driver and therapeutic target for pancreatic cancer. Cold Spring Harb. Perspect. Med.8(9), (2018).
   PubMed Web of Science ®Google Scholar
• Nussinov R , TsaiCJ , JangH. Independent and core pathways in oncogenic KRAS signaling. Expert Rev. Proteomics13(8), 711–716 (2016).
   PubMed Web of Science ®Google Scholar
• Khan AQ , KuttikrishnanS , SiveenKSet al. RAS-mediated oncogenic signaling pathways in human malignancies. Semin. Cancer Biol.54, 1–13 (2019).
   PubMed Web of Science ®Google Scholar
• Peng J , LvJ , PengJ. KRAS mutation is predictive for poor prognosis in rectal cancer patients with neoadjuvant chemoradiotherapy: a systemic review and meta-analysis. Int. J. Colorectal Dis.36(8), 1781–1790 (2021).
   PubMed Web of Science ®Google Scholar
• Chen F , AlphonseMP , LiuY , LiuQ. Targeting mutant KRAS for anticancer therapy. Curr. Top. Med. Chem.19(23), 2098–2113 (2019).
   PubMed Web of Science ®Google Scholar
• Ostrem JM , PetersU , SosML , WellsJA , ShokatKM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature503(7477), 548–551 (2013).
   PubMed Web of Science ®Google Scholar
• Lanman BA , AllenJR , AllenJGet al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J. Med. Chem.63(1), 52–65 (2020).
   PubMed Web of Science ®Google Scholar
• Nakajima EC , DreznerN , LiXet al. FDA approval summary: sotorasib for KRAS G12C-mutated metastatic NSCLC. Clin. Cancer Res.28(8), 1482–1486 (2021).
   Web of Science ®Google Scholar
• Hong DS , FakihMG , StricklerJHet al. KRAS(G12C) inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med.383(13), 1207–1217 (2020).
   PubMed Web of Science ®Google Scholar
• Skoulidis F , LiBT , DyGKet al. Sotorasib for lung cancers with KRAS p.G12C mutation. N. Engl. J. Med.384(25), 2371–2381 (2021).
   PubMed Web of Science ®Google Scholar
• Zhang SS , NagasakaM. Spotlight on sotorasib (AMG 510) for KRAS (G12C) positive non-small cell lung cancer. Lung Cancer (Auckl).12, 115–122 (2021).
   PubMed Web of Science ®Google Scholar
• Canon J , RexK , SaikiAYet al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature575(7781), 217–223 (2019).
   PubMed Web of Science ®Google Scholar
• Muzumdar MD , ChenPY , DoransKJet al. Survival of pancreatic cancer cells lacking KRAS function. Nat. Commun.8(1), 1090 (2017).
   PubMedGoogle Scholar
• Adachi Y , ItoK , HayashiYet al. Epithelial-to-mesenchymal transition is a cause of both intrinsic and acquired resistance to KRAS G12C inhibitor in KRAS G12C-mutant non-small cell lung cancer. Clin. Cancer Res.26(22), 5962–5973 (2020).
   PubMed Web of Science ®Google Scholar
• Awad MM , LiuS , RybkinIIet al. Acquired resistance to KRAS(G12C) inhibition in cancer. N. Engl. J. Med.384(25), 2382–2393 (2021).
   PubMed Web of Science ®Google Scholar
• Zafra MP , ParsonsMJ , KimJet al. An in vivo Kras allelic series reveals distinct phenotypes of common oncogenic variants. Cancer Discov.10(11), 1654–1671 (2020).
   PubMed Web of Science ®Google Scholar
• Jia Y , JiangT , LiXet al. Characterization of distinct types of KRAS mutation and its impact on first-line platinum-based chemotherapy in Chinese patients with advanced non-small cell lung cancer. Oncol. Lett.14(6), 6525–6532 (2017).
   PubMed Web of Science ®Google Scholar
• Misale S , YaegerR , HoborSet al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature486(7404), 532–536 (2012).
   PubMed Web of Science ®Google Scholar
• Molina-Arcas M , MooreC , RanaSet al. Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. Sci. Transl. Med.11(510), eaaw7999 (2019).
   PubMed Web of Science ®Google Scholar
• Prior IA , HancockJF. Ras trafficking, localization and compartmentalized signalling. Semin. Cell Dev. Biol.23(2), 145–153 (2012).
   PubMed Web of Science ®Google Scholar
• Teske C , SchweitzerC , PalamidessiAet al. Modulation of RAB5A early endosome trafficking in response to KRas mediated macropinocytic fluxes in pancreatic cancer cells. Biochem. Biophys. Res. Commun.493(1), 528–533 (2017).
   PubMed Web of Science ®Google Scholar
• Tomas A , FutterCE , EdenER. EGF receptor trafficking: consequences for signaling and cancer. Trends Cell Biol.24(1), 26–34 (2014).
   PubMed Web of Science ®Google Scholar
• Sandilands E , FrameMC. Endosomal trafficking of Src tyrosine kinase. Trends Cell Biol.18(7), 322–329 (2008).
   PubMed Web of Science ®Google Scholar
• Belli S , EspositoD , ServettoA , PesapaneA , FormisanoL , BiancoR. c-Src and EGFR inhibition in molecular cancer therapy: what else can we improve?Cancers (Basel)12(6), (2020).
   Web of Science ®Google Scholar
• Saturno G , LopesF , Niculescu-DuvazIet al. The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers. Ann. Oncol.32(2), 269–278 (2021).
   PubMed Web of Science ®Google Scholar
• Wang SE . Extracellular vesicles and metastasis. Cold Spring Harb. Perspect. Med.10(7), a037275 (2020).
   PubMed Web of Science ®Google Scholar
• Gurung S , PerocheauD , TouramanidouL , BaruteauJ. The exosome journey: from biogenesis to uptake and intracellular signalling. Cell Commun. Signal.19(1), 47 (2021).
   PubMed Web of Science ®Google Scholar
• Hikita T , KuwaharaA , WatanabeR , MiyataM , OneyamaC. Src in endosomal membranes promotes exosome secretion and tumor progression. Sci. Rep.9(1), 3265 (2019).
   PubMedGoogle Scholar
• Jouida A , MccarthyC , FabreA , KeaneMP. Exosomes: a new perspective in EGFR-mutated lung cancer. Cancer Metastasis Rev.40(2), 589–601 (2021).
   PubMed Web of Science ®Google Scholar
• Kalra H , DrummenGP , MathivananS. Focus on extracellular vesicles: introducing the next small big thing. Int. J. Mol. Sci.17(2), 170 (2016).
   PubMed Web of Science ®Google Scholar
• Willms E , CabanasC , MagerI , WoodMJA , VaderP. Extracellular vesicle heterogeneity: subpopulations, isolation techniques, and diverse functions in cancer progression. Front. Immunol.9, 738 (2018).
   PubMed Web of Science ®Google Scholar
• Willms E , JohanssonHJ , MagerIet al. Cells release subpopulations of exosomes with distinct molecular and biological properties. Sci. Rep.6, 22519 (2016).
   PubMed Web of Science ®Google Scholar
• Hanayama R . Emerging roles of extracellular vesicles in physiology and disease. J. Biochem.169(2), 135–138 (2021).
   PubMed Web of Science ®Google Scholar
• King HW , MichaelMZ , GleadleJM. Hypoxic enhancement of exosome release by breast cancer cells. BMC Cancer12, 421 (2012).
   PubMed Web of Science ®Google Scholar
• Wang T , GilkesDM , TakanoNet al. Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. Proc. Natl. Acad. Sci. U. S. A.111(31), E3234–3242 (2014).
   PubMed Web of Science ®Google Scholar
• Becker A , ThakurBK , WeissJM , KimHS , PeinadoH , LydenD. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell30(6), 836–848 (2016).
   PubMed Web of Science ®Google Scholar
• Maacha S , BhatAA , JimenezLet al. Extracellular vesicles-mediated intercellular communication: roles in the tumor microenvironment and anti-cancer drug resistance. Mol. Cancer18(1), 55 (2019).
   PubMedGoogle Scholar
• Akers JC , GondaD , KimR , CarterBS , ChenCC. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neurooncol.113(1), 1–11 (2013).
   PubMed Web of Science ®Google Scholar
• Piper RC , KatzmannDJ. Biogenesis and function of multivesicular bodies. Annu. Rev. Cell Dev. Biol.23, 519–547 (2007).
   PubMed Web of Science ®Google Scholar
• Lu A , TebarF , Alvarez-MoyaBet al. A clathrin-dependent pathway leads to KRas signaling on late endosomes en route to lysosomes. J. Cell Biol.184(6), 863–879 (2009).
   PubMed Web of Science ®Google Scholar
• Tebar F , ChaveroA , AgellNet al. Pleiotropic roles of calmodulin in the regulation of KRas and Rac1 GTPases: functional diversity in health and disease. Int. J. Mol. Sci.21(10), (2020).
   PubMed Web of Science ®Google Scholar
• Hinger SA , AbnerJJ , FranklinJL , JeppesenDK , CoffeyRJ , PattonJG. Rab13 regulates sEV secretion in mutant KRAS colorectal cancer cells. Sci. Rep.10(1), 15804 (2020).
   PubMed Web of Science ®Google Scholar
• Ettelaie C , CollierME , MaraveyasA , EttelaieR. Characterization of physical properties of tissue factor-containing microvesicles and a comparison of ultracentrifuge-based recovery procedures. J. Extracell. Vesicles3, 10.3402/jev.v3.23592 (2014).
   PubMedGoogle Scholar
• Petanidis S , DomvriK , PorpodisKet al. Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation. Biomed. Pharmacother.122, 109461 (2020).
   PubMed Web of Science ®Google Scholar
• Nair SS , KumarR. Chromatin remodeling in cancer: a gateway to regulate gene transcription. Mol. Oncol.6(6), 611–619 (2012).
   PubMed Web of Science ®Google Scholar
• Zahra K , DeyT , Ashish , MishraSP , PandeyU. Pyruvate kinase M2 and cancer: the role of PKM2 in promoting tumorigenesis. Front. Oncol.10, 159 (2020).
   PubMed Web of Science ®Google Scholar
• Sun Q , ChenX , MaJet al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA108(10), 4129–4134 (2011).
   PubMed Web of Science ®Google Scholar
• Tordonato C , MarziMJ , GiangrecoGet al. miR-146 connects stem cell identity with metabolism and pharmacological resistance in breast cancer. J. Cell Biol.220(5), e202009053 (2021).
   PubMed Web of Science ®Google Scholar
• Tsuchiya S , FujiwaraT , SatoFet al. MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1). J. Biol. Chem.286(1), 420–428 (2011).
   PubMed Web of Science ®Google Scholar
• Giannakakis A , SandaltzopoulosR , GreshockJet al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol. Ther.7(2), 255–264 (2008).
   PubMed Web of Science ®Google Scholar
• Anand S , SamuelM , KumarS , MathivananS. Ticket to a bubble ride: cargo sorting into exosomes and extracellular vesicles. Biochim. Biophys. Acta Proteins Proteom.1867(12), 140203 (2019).
   PubMed Web of Science ®Google Scholar
• Chang WH , CerioneRA , AntonyakMA. Extracellular vesicles and their roles in cancer progression. Methods Mol. Biol.2174, 143–170 (2021).
   PubMedGoogle Scholar
• Segev N . Coordination of intracellular transport steps by GTPases. Semin. Cell Dev. Biol.22(1), 33–38 (2011).
   PubMed Web of Science ®Google Scholar
• Demory Beckler M , HigginbothamJN , FranklinJLet al. Proteomic analysis of exosomes from mutant KRAS colon cancer cells identifies intercellular transfer of mutant KRAS. Mol. Cell. Proteomics12(2), 343–355 (2013).
   PubMed Web of Science ®Google Scholar
• Putz U , HowittJ , DoanAet al. The tumor suppressor PTEN is exported in exosomes and has phosphatase activity in recipient cells. Sci. Signal.5(243), ra70 (2012).
   PubMed Web of Science ®Google Scholar
• Sasaki AT , CarracedoA , LocasaleJWet al. Ubiquitination of K-Ras enhances activation and facilitates binding to select downstream effectors. Sci. Signal.4(163), ra13 (2011).
   PubMed Web of Science ®Google Scholar
• Wang HW , NolandC , SiridechadilokBet al. Structural insights into RNA processing by the human RISC-loading complex. Nat. Struct. Mol. Biol.16(11), 1148–1153 (2009).
   PubMed Web of Science ®Google Scholar
• Tien JC , ChughS , GoodrumAEet al. AGO2 promotes tumor progression in KRAS-driven mouse models of non-small cell lung cancer. Proc. Natl. Acad. Sci. USA.118(20), e2026104118 (2021).
   Web of Science ®Google Scholar
• Yuan J , SuZ , GuWet al. MiR-19b and miR-20a suppress apoptosis, promote proliferation and induce tumorigenicity of multiple myeloma cells by targeting PTEN. Cancer Biomark.24(3), 279–289 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang H , WangY , DouJet al. Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis. Oncogene38(9), 1410–1431 (2019).
   PubMed Web of Science ®Google Scholar
• McKenzie AJ , HoshinoD , HongNHet al. KRAS-MEK signaling controls Ago2 sorting into exosomes. Cell Rep.15(5), 978–987 (2016).
   PubMed Web of Science ®Google Scholar
• Prud’homme GJ , GlinkaY , LichnerZ , YousefGM. Neuropilin-1 is a receptor for extracellular miRNA and AGO2/miRNA complexes and mediates the internalization of miRNAs that modulate cell function. Oncotarget7(42), 68057–68071 (2016).
   PubMedGoogle Scholar
• Berasain C , AvilaMA. Amphiregulin. Semin. Cell Dev. Biol.28, 31–41 (2014).
   PubMed Web of Science ®Google Scholar
• Taverna S , PucciM , GiallombardoMet al. Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway. Sci. Rep.7(1), 3170 (2017).
   PubMedGoogle Scholar
• Baillo A , GirouxC , EthierSP. Knock-down of amphiregulin inhibits cellular invasion in inflammatory breast cancer. J. Cell. Physiol.226(10), 2691–2701 (2011).
   PubMed Web of Science ®Google Scholar
• Wang L , WangL , ZhangHet al. AREG mediates the epithelialmesenchymal transition in pancreatic cancer cells via the EGFR/ERK/NFkappaB signalling pathway. Oncol. Rep.43(5), 1558–1568 (2020).
   PubMed Web of Science ®Google Scholar
• Higginbotham JN , DemoryBeckler M , GephartJDet al. Amphiregulin exosomes increase cancer cell invasion. Curr. Biol.21(9), 779–786 (2011).
   PubMed Web of Science ®Google Scholar
• Ohchi T , AkagiY , KinugasaTet al. Amphiregulin is a prognostic factor in colorectal cancer. Anticancer Res.32(6), 2315–2321 (2012).
   PubMed Web of Science ®Google Scholar
• Ioannou MS , McPhersonPS. Regulation of cancer cell behavior by the small GTPase Rab13. J. Biol. Chem.291(19), 9929–9937 (2016).
   PubMed Web of Science ®Google Scholar
• Gu CJ , XieF , ZhangBet al. High glucose promotes epithelial-mesenchymal transition of uterus endometrial cancer cells by increasing ER/GLUT4-mediated VEGF secretion. Cell Physiol. Biochem.50(2), 706–720 (2018).
   PubMedGoogle Scholar
• Wu C , AgrawalS , VasanjiAet al. Rab13-dependent trafficking of RhoA is required for directional migration and angiogenesis. J. Biol. Chem.286(26), 23511–23520 (2011).
   PubMed Web of Science ®Google Scholar
• Sakane A , AbdallahAA , NakanoKet al. Rab13 small G protein and junctional Rab13-binding protein (JRAB) orchestrate actin cytoskeletal organization during epithelial junctional development. J. Biol. Chem.287(51), 42455–42468 (2012).
   PubMed Web of Science ®Google Scholar
• Sahgal P , AlankoJ , IchaJet al. GGA2 and RAB13 promote activity-dependent beta1-integrin recycling. J. Cell Sci.132(11), jcs233387 (2019).
   PubMed Web of Science ®Google Scholar
• Gou D , RamchandranR , PengXet al. miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia. Am. J. Physiol. Lung Cell. Mol. Physiol.303(8), L682–691 (2012).
   PubMed Web of Science ®Google Scholar
• Deberardinis RJ , LumJJ , HatzivassiliouG , ThompsonCB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab.7(1), 11–20 (2008).
   PubMed Web of Science ®Google Scholar
• Tran Q , LeeH , KimCet al. Revisiting the Warburg effect: diet-based strategies for cancer prevention. Biomed. Res. Int.2020, 8105735 (2020).
   PubMed Web of Science ®Google Scholar
• Brown RS , WahlRL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer72(10), 2979–2985 (1993).
   PubMed Web of Science ®Google Scholar
• Semaan A , MunkarahAR , ArabiHet al. Expression of GLUT-1 in epithelial ovarian carcinoma: correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynecol. Oncol.121(1), 181–186 (2011).
   PubMed Web of Science ®Google Scholar
• Wu Q , Ba-AlawiW , DebloisGet al. GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. Nat. Commun.11(1), 4205 (2020).
   PubMed Web of Science ®Google Scholar
• Chen X , WangL , WangH. LINC01638 lncRNA promotes cancer cell proliferation in hepatocellular carcinoma by increasing cancer cell glucose uptake. Oncol. Lett.18(4), 3811–3816 (2019).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Menendez P , HeviaD , Alonso-AriasRet al. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol.17, 112–127 (2018).
   PubMed Web of Science ®Google Scholar
• Basturk O , SinghR , KaygusuzEet al. GLUT-1 expression in pancreatic neoplasia: implications in pathogenesis, diagnosis, and prognosis. Pancreas40(2), 187–192 (2011).
   PubMed Web of Science ®Google Scholar
• Ying H , KimmelmanAC , LyssiotisCAet al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell149(3), 656–670 (2012).
   PubMed Web of Science ®Google Scholar
• Zhang Q , JeppesenDK , HigginbothamJNet al. Mutant KRAS exosomes alter the metabolic state of recipient colonic epithelial cells. Cell. Mol. Gastroenterol. Hepatol.5(4), 627–629.e626 (2018).
   PubMed Web of Science ®Google Scholar
• Hinger SA , ChaDJ , FranklinJLet al. Diverse long RNAs are differentially sorted into extracellular vesicles secreted by colorectal cancer cells. Cell Rep.25(3), 715–725.e714 (2018).
   PubMed Web of Science ®Google Scholar
• Dou Y , ChaDJ , FranklinJLet al. Circular RNAs are down-regulated in KRAS mutant colon cancer cells and can be transferred to exosomes. Sci. Rep.6, 37982 (2016).
   PubMed Web of Science ®Google Scholar
• Pileri P , CampagnoliS , GrandiAet al. FAT1: a potential target for monoclonal antibody therapy in colon cancer. Br. J. Cancer115(1), 40–51 (2016).
   PubMed Web of Science ®Google Scholar
• Kang MH , JeongGS , SmootDTet al. Verteporfin inhibits gastric cancer cell growth by suppressing adhesion molecule FAT1. Oncotarget8(58), 98887–98897 (2017).
   PubMedGoogle Scholar
• Pathak GP , ShahR , KennedyBEet al. RTN4 knockdown dysregulates the AKT pathway, destabilizes the cytoskeleton, and enhances paclitaxel-induced cytotoxicity in cancers. Mol. Ther.26(8), 2019–2033 (2018).
   PubMed Web of Science ®Google Scholar
• O’Brien J , HayderH , ZayedY , PengC. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front. Endocrinol. (Lausanne)9, 402 (2018).
   PubMed Web of Science ®Google Scholar
• Mills J , CapeceM , CocucciE , TessariA , PalmieriD. Cancer-derived extracellular vesicle-associated microRNAs in intercellular communication: one cell’s trash is another cell’s treasure. Int. J. Mol. Sci.20(24), 6109 (2019).
   Web of Science ®Google Scholar
• Ostenfeld MS , JeppesenDK , LaurbergJRet al. Cellular disposal of miR23b by RAB27-dependent exosome release is linked to acquisition of metastatic properties. Cancer Res.74(20), 5758–5771 (2014).
   PubMed Web of Science ®Google Scholar
• Farahani M , RubbiC , LiuL , SlupskyJR , KalakondaN. CLL exosomes modulate the transcriptome and behaviour of recipient stromal cells and are selectively enriched in miR-202-3p. PLoS One10(10), e0141429 (2015).
   PubMed Web of Science ®Google Scholar
• Vu LT , PengB , ZhangDXet al. Tumor-secreted extracellular vesicles promote the activation of cancer-associated fibroblasts via the transfer of microRNA-125b. J. Extracell. Vesicles8(1), 1599680 (2019).
   PubMed Web of Science ®Google Scholar
• Cha DJ , FranklinJL , DouYet al. KRAS-dependent sorting of miRNA to exosomes. Elife4, e07197 (2015).
   PubMed Web of Science ®Google Scholar
• Ye Y , LiSL , WangJJ. miR-100-5p downregulates mTOR to suppress the proliferation, migration, and invasion of prostate cancer cells. Front. Oncol.10, 578948 (2020).
   PubMed Web of Science ®Google Scholar
• Zhang H , YangK , RenTet al. miR-100-5p inhibits malignant behavior of chordoma cells by targeting IGF1R. Cancer Manag. Res.12, 4129–4137 (2020).
   PubMed Web of Science ®Google Scholar
• Sheedy P , MedarovaZ. The fundamental role of miR-10b in metastatic cancer. Am. J. Cancer Res.8(9), 1674–1688 (2018).
   PubMed Web of Science ®Google Scholar
• Yanez-Mo M , SiljanderPR , AndreuZet al. Biological properties of extracellular vesicles and their physiological functions. J. Extracell. Vesicles4, 27066 (2015).
   PubMed Web of Science ®Google Scholar
• Juan T , FurthauerM. Biogenesis and function of ESCRT-dependent extracellular vesicles. Semin. Cell Dev. Biol.74, 66–77 (2018).
   PubMed Web of Science ®Google Scholar
• Jackson KK , PowellRR , BruceTF , MarcusRK. Rapid isolation of extracellular vesicles from diverse biofluid matrices via capillary-channeled polymer fiber solid-phase extraction micropipette tips. Analyst146(13), 4314–4325 (2021).
   PubMed Web of Science ®Google Scholar
• Shang A , GuC , ZhouCet al. Exosomal KRAS mutation promotes the formation of tumor-associated neutrophil extracellular traps and causes deterioration of colorectal cancer by inducing IL-8 expression. Cell Commun. Signal.18(1), 52 (2020).
   PubMed Web of Science ®Google Scholar
• Mulcahy LA , PinkRC , CarterDR. Routes and mechanisms of extracellular vesicle uptake. J. Extracell. Vesicles3, 10.3402/jev.v3.24641 (2014).
   PubMedGoogle Scholar
• Nakase I , KobayashiNB , Takatani-NakaseT , YoshidaT. Active macropinocytosis induction by stimulation of epidermal growth factor receptor and oncogenic Ras expression potentiates cellular uptake efficacy of exosomes. Sci. Rep.5, 10300 (2015).
   PubMed Web of Science ®Google Scholar
• Jiang W , LiH , LiuXet al. Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression. Theranostics10(25), 11507–11519 (2020).
   PubMed Web of Science ®Google Scholar
• Kamerkar S , LebleuVS , SugimotoHet al. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer. Nature546(7659), 498–503 (2017).
   PubMed Web of Science ®Google Scholar
• McAndrews KM , XiaoF , ChronopoulosA , LebleuVS , KugeratskiFG , KalluriR. Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras(G12D) in pancreatic cancer. Life Sci. Alliance4(9), e202000875 (2021).
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I , ShawAT. Tumour heterogeneity and resistance to cancer therapies. Nat. Rev. Clin. Oncol.15(2), 81–94 (2018).
   PubMed Web of Science ®Google Scholar
• Eng SK , ImtiazIR , GohBH , MingLC , LimYC , LeeWL. Does KRAS play a role in the regulation of colon cancer cells-derived exosomes?Biology (Basel)10(1), 58 (2021).
   PubMedGoogle Scholar
• Lobb RJ , Van AmerongenR , WiegmansA , HamS , LarsenJE , MollerA. Exosomes derived from mesenchymal non-small cell lung cancer cells promote chemoresistance. Int. J. Cancer141(3), 614–620 (2017).
   PubMed Web of Science ®Google Scholar
• Drapela S , BouchalJ , JollyMK , CuligZ , SoucekK. ZEB1: a critical regulator of cell plasticity, DNA damage response, and therapy resistance. Front. Mol. Biosci.7, 36 (2020).
   PubMed Web of Science ®Google Scholar
• Cui Y , QinL , TianDet al. ZEB1 promotes chemoresistance to cisplatin in ovarian cancer cells by suppressing SLC3A2. Chemotherapy63(5), 262–271 (2018).
   PubMed Web of Science ®Google Scholar
• Orellana-Serradell O , HerreraD , CastellonEA , ContrerasHR. The transcription factor ZEB1 promotes chemoresistance in prostate cancer cell lines. Asian J. Androl.21(5), 460–467 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang X , ZhangZ , ZhangQet al. ZEB1 confers chemotherapeutic resistance to breast cancer by activating ATM. Cell Death Dis.9(2), 57 (2018).
   PubMedGoogle Scholar
• Lennerz JK , StenzingerA. Allelic ratio of KRAS mutations in pancreatic cancer. Oncologist20(4), e8–e9 (2015).
   PubMedGoogle Scholar
• Chang WH , NguyenTT , HsuCHet al. KRAS-dependent cancer cells promote survival by producing exosomes enriched in Survivin. Cancer Lett.517, 66–77 (2021).
   PubMed Web of Science ®Google Scholar
• Garg H , SuriP , GuptaJC , TalwarGP , DubeyS. Survivin: a unique target for tumor therapy. Cancer Cell Int.16, 49 (2016).
   PubMed Web of Science ®Google Scholar
• Zhang Y , YanH , LiR , GuoY , ZhengR. High expression of Survivin predicts poor prognosis in cervical squamous cell carcinoma treated with paclitaxel and carboplatin. Medicine (Baltimore)98(20), e15607 (2019).
   PubMed Web of Science ®Google Scholar
• Zhang J , ZhuZ , SunZ , SunX , WangZ , XuH. Survivin gene expression increases gastric cancer cell lymphatic metastasis by upregulating vascular endothelial growth factor-C expression levels. Mol. Med. Rep.9(2), 600–606 (2014).
   PubMed Web of Science ®Google Scholar
• Dohi T , BeltramiE , WallNR , PlesciaJ , AltieriDC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J. Clin. Invest.114(8), 1117–1127 (2004).
   PubMed Web of Science ®Google Scholar
• Or YY , ChowAK , NgLet al. Survivin depletion inhibits tumor growth and enhances chemosensitivity in hepatocellular carcinoma. Mol. Med. Rep.10(4), 2025–2030 (2014).
   PubMed Web of Science ®Google Scholar
• Rauch A , CarlstedtA , EmmerichCet al. Survivin antagonizes chemotherapy-induced cell death of colorectal cancer cells. Oncotarget9(45), 27835–27850 (2018).
   PubMedGoogle Scholar
• Kreger BT , JohansenER , CerioneRA , AntonyakMA. The enrichment of survivin in exosomes from breast cancer cells treated with paclitaxel promotes cell survival and chemoresistance. Cancers (Basel)8(12), 111 (2016).
   PubMed Web of Science ®Google Scholar
• Kim HS , KimSC , KimSJet al. Identification of a radiosensitivity signature using integrative metaanalysis of published microarray data for NCI-60 cancer cells. BMC Genomics13, 348 (2012).
   PubMed Web of Science ®Google Scholar
• Baghban R , RoshangarL , Jahanban-EsfahlanRet al. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal.18(1), 59 (2020).
   PubMed Web of Science ®Google Scholar
• Zhou J , TangZ , GaoS , LiC , FengY , ZhouX. Tumor-associated macrophages: recent insights and therapies. Front. Oncol.10, 188 (2020).
   PubMed Web of Science ®Google Scholar
• Shaul ME , FridlenderZG. Tumour-associated neutrophils in patients with cancer. Nat. Rev. Clin. Oncol.16(10), 601–620 (2019).
   PubMed Web of Science ®Google Scholar
• Van Dalen FJ , Van StevendaalM , FennemannFL , VerdoesM , IlinaO. Molecular repolarisation of tumour-associated macrophages. Molecules24(1), (2018).
   PubMed Web of Science ®Google Scholar
• Jayasingam SD , CitartanM , ThangTH , MatZin AA , AngKC , Ch’ngES. Evaluating the polarization of tumor-associated macrophages into M1 and M2 phenotypes in human cancer tissue: technicalities and challenges in routine clinical practice. Front. Oncol.9, 1512 (2019).
   PubMed Web of Science ®Google Scholar
• Dai E , HanL , LiuJet al. Autophagy-dependent ferroptosis drives tumor-associated macrophage polarization via release and uptake of oncogenic KRAS protein. Autophagy16(11), 2069–2083 (2020).
   PubMed Web of Science ®Google Scholar
• Li J , CaoF , YinHLet al. Ferroptosis: past, present and future. Cell Death Dis.11(2), 88 (2020).
   PubMed Web of Science ®Google Scholar
• Ito F , KatoK , YanatoriI , MuroharaT , ToyokuniS. Ferroptosis-dependent extracellular vesicles from macrophage contribute to asbestos-induced mesothelial carcinogenesis through loading ferritin. Redox Biol.47, 102174 (2021).
   PubMed Web of Science ®Google Scholar
• Kierdorf K , FritzG. RAGE regulation and signaling in inflammation and beyond. J. Leukoc. Biol.94(1), 55–68 (2013).
   PubMed Web of Science ®Google Scholar
• Hu H , HangJJ , HanT , ZhuoM , JiaoF , WangLW. The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer. Tumour Biol.37(7), 8657–8664 (2016).
   PubMedGoogle Scholar
• Klingen TA , ChenY , AasH , WikE , AkslenLA. Tumor-associated macrophages are strongly related to vascular invasion, non-luminal subtypes, and interval breast cancer. Hum. Pathol.69, 72–80 (2017).
   PubMed Web of Science ®Google Scholar
• Sionov RV , FridlenderZG , GranotZ. The multifaceted roles neutrophils play in the tumor microenvironment. Cancer Microenviron.8(3), 125–158 (2015).
   PubMedGoogle Scholar
• Shaul ME , LevyL , SunJet al. Tumor-associated neutrophils display a distinct N1 profile following TGFbeta modulation: a transcriptomics analysis of pro- vs. antitumor TANs. Oncoimmunology5(11), e1232221 (2016).
   PubMed Web of Science ®Google Scholar
• Mishalian I , BayuhR , EruslanovEet al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17 – a new mechanism of impaired antitumor immunity. Int. J. Cancer135(5), 1178–1186 (2014).
   PubMed Web of Science ®Google Scholar
• Munder M , SchneiderH , LucknerCet al. Suppression of T-cell functions by human granulocyte arginase. Blood108(5), 1627–1634 (2006).
   PubMed Web of Science ®Google Scholar
• Najmeh S , Cools-LartigueJ , RayesRFet al. Neutrophil extracellular traps sequester circulating tumor cells via beta1-integrin mediated interactions. Int. J. Cancer140(10), 2321–2330 (2017).
   PubMed Web of Science ®Google Scholar
• Takeshima T , PopLM , LaineA , IyengarP , VitettaES , HannanR. Key role for neutrophils in radiation-induced antitumor immune responses: potentiation with G-CSF. Proc. Natl. Acad. Sci. USA.113(40), 11300–11305 (2016).
   PubMed Web of Science ®Google Scholar
• Jung HS , GuJ , KimJE , NamY , SongJW , KimHK. Cancer cell-induced neutrophil extracellular traps promote both hypercoagulability and cancer progression. PLoS One14(4), e0216055 (2019).
   PubMed Web of Science ®Google Scholar
• Leal AC , MizuriniDM , GomesTet al. Tumor-derived exosomes induce the formation of neutrophil extracellular traps: implications for the establishment of cancer-associated thrombosis. Sci. Rep.7(1), 6438 (2017).
   PubMed Web of Science ®Google Scholar
• Alfaro C , TeijeiraA , OnateCet al. Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs). Clin. Cancer Res.22(15), 3924–3936 (2016).
   PubMed Web of Science ®Google Scholar
• Gilbert AE , KaragiannisP , DodevTet al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One6(4), e19330 (2011).
   PubMed Web of Science ®Google Scholar
• Ammirante M , LuoJL , GrivennikovS , NedospasovS , KarinM. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature464(7286), 302–305 (2010).
   PubMed Web of Science ®Google Scholar
• Olkhanud PB , DamdinsurenB , BodogaiMet al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4(+) T cells to T-regulatory cells. Cancer Res.71(10), 3505–3515 (2011).
   PubMed Web of Science ®Google Scholar
• Tay RE , RichardsonEK , TohHC. Revisiting the role of CD4(+) T cells in cancer immunotherapy-new insights into old paradigms. Cancer Gene Ther.28(1-2), 5–17 (2021).
   PubMed Web of Science ®Google Scholar
• Laidlaw BJ , CraftJE , KaechSM. The multifaceted role of CD4(+) T cells in CD8(+) T cell memory. Nat. Rev. Immunol.16(2), 102–111 (2016).
   PubMed Web of Science ®Google Scholar
• Nonaka K , SaioM , UmemuraNet al. Th1 polarization in the tumor microenvironment upregulates the myeloid-derived suppressor-like function of macrophages. Cell. Immunol.369, 104437 (2021).
   PubMed Web of Science ®Google Scholar
• Zdanov S , MandapathilM , AbuEid Ret al. Mutant KRAS conversion of conventional T cells into regulatory T cells. Cancer Immunol. Res.4(4), 354–365 (2016).
   PubMed Web of Science ®Google Scholar
• Kalvala A , WalletP , YangLet al. Phenotypic switching of naive T cells to immune-suppressive Treg-like cells by mutant KRAS. J. Clin. Med.8(10), 1726 (2019).
   PubMed Web of Science ®Google Scholar
• Nishikawa H , SakaguchiS. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol.27, 1–7 (2014).
   PubMed Web of Science ®Google Scholar
• Raskov H , OrhanA , ChristensenJP , GogenurI. Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy. Br. J. Cancer124(2), 359–367 (2021).
   PubMed Web of Science ®Google Scholar